文献速递白血病

索拉非尼联合化疗一线治疗FLT3-ITD阳性急性髓系白血病

[Sorafenib in combination with chemotherapy as first-line therapy for FLT3-ITD positive acute myeloid leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2017-01-01

回顾性分析2013年1月至2016年8月河南省肿瘤医院53例初治FLT3-ITD突变阳性AML患者,对比化疗联合或不联合索拉非尼的疗效。联合组与单纯化疗组完全缓解率分别为86.4%(19/22)和35.5%(11/31),1年总生存率分别为78.3%和50.0%(P=0.041),1年无进展生存率分别为75.9%和42.4%(P=0.044)。

要点

  • 53例FLT3-ITD阳性AML中M5型占41.5%,高白细胞(>10×10^9/L)者占94.3%。
  • 索拉非尼联合化疗组完全缓解率86.4%(19/22)vs 单纯化疗组35.5%(11/31),P<0.001。
  • 联合组1年总生存率78.3% vs 单纯化疗组50.0%(P=0.041)。

核心结论

  • FLT3-ITD突变阳性AML具有初发时外周血WBC及骨髓原始细胞比例高、与M5亚型高度伴随的临床特征,索拉非尼联合化疗可明显改善该类患者的诱导缓解率及短期生存。

研究设计与样本

  • 回顾性分析2013年1月至2016年8月河南省肿瘤医院确诊的53例初治伴FLT3-ITD突变AML患者的临床资料。
  • 对比分析化疗联合与不联合索拉非尼治疗的生物学特征及临床疗效。

主要发现

  • 53例FLT3-ITD突变阳性AML患者中M5型所占比例最高(41.5%)。
  • 外周血WBC中位数为61.00(0.98~920.00)×10^9/L,高白细胞计数(>10×10^9/L)患者50例(94.3%)。
  • 骨髓原始细胞比例中位数为0.730(0.234~0.966)。
  • 53例患者总诱导缓解率为56.6%(30/53)。
  • 索拉非尼联合化疗组与单纯化疗组诱导缓解率分别为86.4%(19/22)和35.5%(11/31),差异有统计学意义(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the clinical features of acute myeloid leukemia patients with Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation and the therapeutic effect of sorafenib in combination with chemotherapy as first-line therapy for these patients. Methods: Clinical features and therapeutic effect were retrospectively analyzed in 53 AML patients with FLT3-ITD mutation diagnosed in Henan Cancer Hospital from January 2013 to August 2016. The biological characteristics and clinical efficacy of chemotherapy in combination with or without Sorafeinb were analyzed. Results: FLT3-ITD mutation was identified in 53 AML patients, 22 cases (41.5%) were M(5) subtype. The median of the peripheral WBC was 61.00 (0.98-920.00) ×10(9)/L, and there were 50 (94.3%) patients with WBC>10×10(9)/L. The median of blast cell in bone marrow was 0.730 (0.234-0.966) . The total remission rate of all these 53 patients was 56.6% (30/53) . The complete remission (CR) rates in patients treated with chemotherapy in combination with sorafenib and patients with chemotherapy alone were 86.4% (19/22) and 35.5% (11/31) , respectively. The 1-year overall survival rates of the two groups were 78.3%% and 50.0% (P=0.041) , and 1-year progression free survival rates were 75.9% and 42.4% (P=0.044) , respectively. Conclusion: AML patients with FLT3-ITD mutation have the characteristics of high peripheral WBC, high blast cells in bone marrow and accompanying with M(5) subtype. Sorafeinb combined with chemotherapy can significantly improve CR rate and short term survival. 目的: 探讨Fms样酪氨酸激酶3内部串联重复(FLT3-ITD)突变阳性的急性髓系白血病(AML)患者的临床特征及预后,分析索拉非尼联合化疗一线治疗该类患者的疗效。 方法: 回顾性分析2013年1月至2016年8月河南省肿瘤医院确诊的53例初治伴FLT3-ITD突变的AML患者资料,研究该类患者发病时生物学特征,并对比分析化疗联合与不联合索拉非尼治疗的疗效。 结果: 53例FLT3-ITD突变阳性AML患者中,M(5)型所占比例最高(41.5%),外周血WBC中位数为61.00(0.98~920.00)×10(9)/L,其中高白细胞计数(>10×10(9)/L)患者50例(94.3%);骨髓原始细胞比例中位数为0.730(0.234~0.966)。53例患者总诱导缓解率为56.6%,索拉非尼联合化疗组与单纯化疗组诱导缓解率分别为86.4%(19/22)和35.5%(11/31),差异有统计学意义(P<0.001)。索拉非尼联合化疗组与单纯化疗组患者1年总生存率分别为78.3%和50.0%(P=0.041),1年无进展生存率分别为75.9%和42.4%(P=0.044)。 结论: FLT3-ITD突变阳性AML具有初发时外周血WBC及骨髓原始细胞比例高、与M(5)亚型高度伴随的临床特征,索拉非尼联合化疗可明显改善该类患者的诱导缓解率及短期生存。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang QY, Wei XD, Yin QS, et al. [Sorafenib in combination with chemotherapy as first-line therapy for FLT3-ITD positive acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28565742. doi:10.3760/cma.j.issn.0253-2727.2017.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。